Complete financial analysis of Live Verdure Ltd (LV1.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Live Verdure Ltd, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- China e-Wallet Payment Group Limited (0802.HK) Income Statement Analysis – Financial Results
- Nagreeka Exports Limited (NAGREEKEXP.NS) Income Statement Analysis – Financial Results
- PT. Gajah Tunggal Tbk (GJTL.JK) Income Statement Analysis – Financial Results
- Aozora Bank, Ltd. (8304.T) Income Statement Analysis – Financial Results
- Pharmarise Holdings Corporation (2796.T) Income Statement Analysis – Financial Results
Live Verdure Ltd (LV1.AX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://liveverdure.com.au
About Live Verdure Ltd
Live Verdure Ltd, together with its subsidiaries, engages in the development and sale of plant-based products in Australia. It offers food and nutraceutical products based on hemp seeds; and skincare products under the 13 Seeds and 8 Seeds brand names through wholesale, distribution, retail, and online channels. The company was formerly known as 13 Seeds Ltd. and changed its name to Live Verdure Limited in October 2020. Live Verdure Ltd was incorporated in 2016 and is based in Melbourne, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.94M | 2.22M | 1.89M | 607.53K | 398.67K | 165.34K | 247.45K |
| Cost of Revenue | 1.24M | 877.82K | 445.64K | 327.39K | 624.15K | 352.86K | 306.99K |
| Gross Profit | 695.99K | 1.34M | 1.44M | 280.14K | -225.48K | -187.51K | -59.54K |
| Gross Profit Ratio | 35.95% | 60.39% | 76.38% | 46.11% | -56.56% | -113.41% | -24.06% |
| Research & Development | 870.44K | 584.28K | 488.58K | 165.43K | 117.18K | 0.00 | 0.00 |
| General & Administrative | 11.51M | 2.12M | 1.00M | 2.25M | 350.64K | 96.32K | 78.06K |
| Selling & Marketing | 851.96K | 1.54M | 3.20M | 1.22M | 851.59K | 166.96K | 39.89K |
| SG&A | 12.37M | 4.24M | 4.20M | 3.46M | 992.27K | 324.14K | 127.83K |
| Other Expenses | 0.00 | 188.68K | 148.98K | 126.73K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 13.24M | 4.24M | 4.70M | 3.64M | 992.27K | 324.14K | 127.83K |
| Cost & Expenses | 14.48M | 5.12M | 5.14M | 3.96M | 1.62M | 676.99K | 434.82K |
| Interest Income | 0.00 | 1.71K | 1.02K | 1.25K | 522.00 | 3.29K | 0.00 |
| Interest Expense | 83.56K | 124.96K | 859.55K | 230.42K | 44.65K | 0.00 | 0.00 |
| Depreciation & Amortization | 35.75K | 41.64K | 5.62K | 7.02K | 80.01K | 19.44K | 9.17K |
| EBITDA | -12.51M | -2.67M | -3.10M | -3.22M | -1.14M | -423.53K | -178.85K |
| EBITDA Ratio | -646.25% | -128.98% | -164.23% | -530.01% | -285.38% | -297.69% | -72.01% |
| Operating Income | -12.54M | -2.90M | -3.10M | -3.23M | -1.22M | -511.65K | -187.37K |
| Operating Income Ratio | -647.73% | -130.86% | -164.53% | -531.16% | -305.45% | -309.45% | -75.72% |
| Total Other Income/Expenses | -367.67K | -164.89K | -748.94K | -144.31K | -100.75K | 24.89K | -3.43K |
| Income Before Tax | -12.91M | -2.99M | -3.96M | -3.46M | -1.32M | -486.76K | -190.80K |
| Income Before Tax Ratio | -666.72% | -134.77% | -210.08% | -569.09% | -330.72% | -294.39% | -77.10% |
| Income Tax Expense | 0.00 | -152.08K | 1.01M | 357.14K | 4.00 | -40.50K | -82.00 |
| Net Income | -12.91M | -2.83M | -3.96M | -3.46M | -1.32M | -446.26K | -190.71K |
| Net Income Ratio | -666.72% | -127.90% | -210.08% | -569.09% | -330.72% | -269.90% | -77.07% |
| EPS | -0.11 | -0.04 | -0.07 | -0.06 | -0.02 | -0.01 | 0.00 |
| EPS Diluted | -0.11 | -0.04 | -0.07 | -0.06 | -0.02 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 112.30M | 73.24M | 55.36M | 55.25M | 55.25M | 55.25M | 55.25M |
| Weighted Avg Shares Out (Dil) | 112.30M | 73.24M | 55.36M | 55.25M | 55.25M | 55.25M | 55.25M |
Source: https://incomestatements.info
Category: Stock Reports